{"product_id":"quantitative-drug-safety-and-benefit-risk-evaluation-practical-and-cross-disciplinary-approaches-paperback","title":"Quantitative Drug Safety and Benefit Risk Evaluation: Practical and Cross-Disciplinary Approaches - Paperback","description":"\u003cdiv\u003e\u003cp style=\"text-align: right;\"\u003e\u003ca href=\"https:\/\/reportcopyrightinfringement.com\/\" target=\"_blank\" rel=\"nofollow\"\u003e\u003cb\u003eReport copyright infringement\u003c\/b\u003e\u003c\/a\u003e\u003c\/p\u003e\u003c\/div\u003e\u003cp\u003eby \u003cb\u003eWilliam Wang\u003c\/b\u003e (Editor), \u003cb\u003eMelvin Munsaka\u003c\/b\u003e (Editor), \u003cb\u003eJames Buchanan\u003c\/b\u003e (Editor)\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003eThis book provides a comprehensive coverage on safety monitoring methodologies, covering both global trends and regional initiatives. Pharmacovigilance has traditionally focused on the handling of individual adverse event reports however recently there had been a shift towards aggregate analysis to better understand the scope of product risks.\u003c\/p\u003e\u003ch3\u003eAuthor Biography\u003c\/h3\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003e\u003cb\u003eDr. William (Bill) Wang\u003c\/b\u003e is currently Executive Director in the department of Biostatistics and Research Decision Sciences, Merck Research Laboratories, where he has worked for 20+ years. Bill has served as the deputy topics-leader for the ICH E17 Working Group and has co-chaired the ASA Biopharmaceutical Safety Working Group. He is an elected ASA Fellow.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eDr. Melvin S. Munsaka\u003c\/b\u003e is currently Senior Director and Head of Safety Statistics at AbbVie. He has more than 25 years of industry experience. He is a member of the ASA Biopharmaceutical Safety Scientific Working Group, DIA Bayesian Scientific Working Group, and the PHUSE Safety Analytics Working Group\u003c\/p\u003e\u003cp\u003e\u003cb\u003eDr. James Buchanan, \u003c\/b\u003e president of Covilance LLC, has 30+ years of drug safety experience in the pharmaceutical industry. He is a co-lead of the ASA Biopharmaceutical Safety Working Group and the Interactive Safety Graphics taskforce that is developing novel, open-source, interactive graphical tools to evaluate drug safety issues.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eDr. Judy X. Li\u003c\/b\u003e is currently Senior Director, Biostatistics Lead for San Diego site Bristol Myers Squibb. She also has extensive experience working at the US Food and Drug Administration as a master statistical reviewer and supervisory mathematical statistician. She is the founding co-chair of the ASA Biopharmaceutical Safety Working Group.\u003c\/p\u003e\n            \u003cdiv\u003e\n\u003cstrong\u003eNumber of Pages:\u003c\/strong\u003e 382\u003c\/div\u003e\n            \u003cdiv\u003e\n\u003cstrong\u003eDimensions:\u003c\/strong\u003e 0.83 x 9.21 x 6.14 IN\u003c\/div\u003e\n            \u003cdiv\u003e\n\u003cstrong\u003eIllustrated:\u003c\/strong\u003e Yes\u003c\/div\u003e\n            \u003cdiv\u003e\n\u003cstrong\u003ePublication Date:\u003c\/strong\u003e January 29, 2024\u003c\/div\u003e\n            ","brand":"BooksCloud","offers":[{"title":"Default Title","offer_id":52241507516690,"sku":"9781032191119","price":118.24,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0941\/2211\/5346\/files\/k7rM-4bT_E9781032191119.webp?v=1777899744","url":"https:\/\/ckbookstore.net\/products\/quantitative-drug-safety-and-benefit-risk-evaluation-practical-and-cross-disciplinary-approaches-paperback","provider":"CK BOOKSTORE","version":"1.0","type":"link"}